people), and prophylactic modality used might be invoked, the Dutch and Japanese studies were in late preterm infants. It is unlikely that the antibody (palivizumab or motavizumab) played a part, since both prevent admission to hospital for RSV equally efficaciously. An examination of the rates of the measured outcomes and the atopic parental background in the placebo group might explain some of these discrepant results. The rates of medically attended recurrent wheeze in the palivizumab studies 2-4 were about 20-30 times higher than in the motavizumab study. 5 The rates of asthma and atopy in families were at least half that of Japan 3 and a quarter that of the Canadian and European study. The most striking difference though is the extremely low rate of medically attended recurrent wheezing. Many other active and passive prophylaxis trials to prevent RSV are either ongoing or being planned in both preterm and The diff erences in these studies, done over a span of almost 20 years, are outlined in the table. In the fi rst four studies, all done in preterm infants with 1 or without chronic lung disease, 2-4 there were reductions in recurrent wheezing either reported by a parent 4 or medically attended (range 47-66%). 2, 3 In the only study to examine the effect of preventing RSV in the fi rst year of life on subsequent lung function, there was an impact on lung function as measured by the ratio of forced expiratory volume in 1 s to forced vital capacity. Clostridium difficile infection. Untoward microbiota alteration is even more concerning in the light of the recently described influence of bacterial diversity and specifi cally gastrointestinal bacteria (eg, Bifi dobacterium species) on the outcomes of chemotherapy and haematopoietic stem-cell trans plantation. In chemotherapy recipients, the benefits of quinolone prophylaxis do not outweigh the risks. Thus, assessing a putative increase in mortality along with the global rise in antibiotic resistance might not be the ideal focus of our eff orts. We should instead wisely limit antibiotic prophylaxis to settings of substantial benefit proven in randomised controlled trials. antibiotic-based decolonisation or targeted prophylaxis approaches. The assessment of antibiotic prophylaxis in chemotherapy recipients however, appears challenging. The efficacy of antibiotic prophylaxis in cancer and especially during neutropenia is arguable. The referenced meta-analysis 2 includes only one study purportedly showing a significant survival benefit for quinolone prophylaxis. However, this study investigated a selective decolonisation regimen rather than quinolone prophylaxis. Furthermore, not only did that study's intervention include antifungals but also a control group without co-trimoxazole, as opposed to parts of the intervention group. Because the study was done more than 35 years ago, its applicability today is questionable. Two recent, welldesigned, randomised, controlled, and sufficiently powered studies assessing quinolone prophylaxis showed reduced incidences of fever and infection, but no survival benefi t of prophylaxis over placebo. 4, 5 Beyond the uncertain efficacy of antibiotic prophylaxis in oncology, the question whether resistant organisms pose a threat to cancer patients needs to be addressed. A causal relation between infection or colonisation with multi-resistant bacteria and increased mortality in chemotherapy recipients has not been conclusively established. Recent findings, including our own work cited by Teillant and colleagues, show that appropriate empirical antibiotic treatment in chemotherapy recipients yields similar outcomes for infections by multi-resistant and susceptible bacteria. We further showed rectal screening as an eff ective and feasible approach guiding initial empirical treatment in febrile neutropenia. 1 Additionally, the broader eff ects of antibiotic prophylaxis in oncology patients remain a concern. Apart from promoting resistance, 1 quino lone prophylaxis precedes
Burden and benefi t of antibiotic prophylaxis in cancer chemotherapy
We want to congratulate Aude Teillant and colleagues 1 for their interesting and important analysis, and especially for pointing out the ramifications of increasing antibiotic resistance in settings beyond treatment of infections. Novel approaches to surgical site infection prophylaxis are indeed needed. Immunological approaches (eg, passive or active immunisation) might be less prone to diminishing efficacy through emerging anti microbial resistance than
